HCW Biologics Inc. Common Stock
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat pancreatic cancer; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201 and HCW9206, novel immunotherapeutic for memory-like natural killer cells, cancer, and pathogens; HCW11-006, an immune cell stimulator; HCW11-002 and HCW11-0027, which are immune checkpoint inhibitors to treat oncology and other senescence-associated indications; and HCW11-018, a fusions and immune cell engagers to treat cancer. The company has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecules. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Open HCWB dashboard ↗Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
Open SUPN dashboard ↗